Trevena Inc.’s novel AT1 receptor-selective agonist TRV027 will be included in an international, adaptive Phase II/III study as a potential treatment for COVID-19 patients. The study is being supported by multiple international governments and global research organizations.
NCI Technology Opportunities Webinar: “Complete Tumor Regression Seen in Colon Cancer and Leukemia Animal Models with a Novel High Efficacy Fluorinated Cytidine Therapeutic Compound”
The National Cancer Institute (NCI), Technology Transfer Center (TTC) will host a webinar to highlight a cancer therapeutic technology for collaborative development and/or licensing. The webinar presented by the technology inventor, Dr. Joel Morris, will highlight NCI’s novel, therapeutic fluorinated cytidine compound that shows high efficacy against colon cancer and leukemia. Studies indicated that the therapeutic compound can produce complete regression in xenograph mouse models with minimal effects on body weight. Registration is free.
ATCC, the world’s premier biological materials management and standards organization, today announced that it has been awarded a three-year, $9.86 million task order contract by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to manage and operate its HIV Reagent Program, formerly known as the AIDS Reagent Program. ATCC is tasked to supply the HIV/AIDS research community with no-cost, high-quality materials supporting the development and evaluation of therapeutics, vaccines, and diagnostics.
The George Washington University (GW) Technology Commercialization Office is pleased to host the inaugural DC Startup Showcase.DC Startup Showcase will present companies developing disruptive healthcare innovations. Log on to our [….]
Join fellow biotech and bioscience professionals for a quarterly series that brings together the Frederick County and surrounding areas’ bio community for an inside look at local advances. This webinar [….]
BioFactura Awarded $67.4 Million Advanced Development Contract for its Smallpox Biodefense Therapeutic
BioFactura Awarded $67.4 Million Advanced Development Contract for its Smallpox Biodefense Therapeutic Frederick, Maryland, September 26, 2019: BioFactura, Inc. today announced a contract awarded by the Biomedical Advanced Research and [….]